期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小肾癌的治疗策略 被引量：5

暂未订购
导出
摘要 肾癌在我国泌尿外科恶性肿瘤中占第二位仅次于膀胱癌,其发病率呈现逐年上升趋势。随着人们健康意识的提高以及B超、CT等影像检查被广泛地应用,肾癌的检出率逐年增高,其中小肾癌占相当比例。因为小肾癌多为低分期、低分级肿瘤,5年生存率高,故其治疗一直被泌尿外科医师所关注。由于对小肾脏肿瘤自然史的进一步观察研究、人们对术后器官功能保存和生活质量要求的提高以及泌尿外科微创技术的发展,保留肾单位手术和微创手术被越来越多地应用于小肾癌的治疗。目前国内在小肾癌的治疗中根治性肾切除手术仍然被广泛应用,保留肾单位手术正在逐步推广开展,微创治疗方法是近年研究的一个热点。本文就目前小肾癌的各种治疗方法现状及其选择策略作一综述。
作者 王权 周文生
机构地区 安徽省蚌埠医学院第一附属医院泌尿外科
出处 《中华全科医学》 2010年第12期1590-1592,共3页 Chinese Journal of General Practice
关键词 小肾癌 主动监测 手术 微创治疗
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1顾方六,肾肿瘤[M]//吴阶平.泌尿外科学.上卷.济南:山东科学技术出版社,2004:895-896.
  • 2程文,周四维,高建平,张征宇,葛京平,周文泉,马宏青,周水根,魏武,薛松,梁培禾,李汉平,蔡荣星.298例偶发性肾细胞癌与312例症状性肾细胞癌临床分析[J].江苏医药,2003,29(6):454-455. 被引量：11
  • 3Kato M, Suzuki T, Suzuki Y, et al. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis [ J ]. Urol,2004,172 (3) : 863-866.
  • 4Chawla SN, Crispen PL, Hanlon AL, et al. The natural history of observed enhancing renal masses : meta-analysis and review of the world literature [ J ]. Urol, 2006,175 ( 2 ) :425-431.
  • 5Wong JA, Rendon RA. Progression to metastatic disease from a small . renal cell carcinoma prospectively followed with an active surveillance protocol[ J]. Can Urol Assoc,2007,1 (2) :120-122.
  • 6Rendon RA. Active surveillance as the preferred management option for small renal masses[J]. Can Urol Assoc,2010,4(2) :136-138.
  • 7Sowery RD, Siemens DR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting [ J ]. Can J Urol, 2004,11 ( 5 ) : 2407 -2410.
  • 8Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer ( EORTC ) randomized phase 3 trial 30881 [ J]. Eur Urol,2009,55 ( 1 ) :28-34.
  • 9Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours:a retrospective cohort study [ J ]. Lancet Oneol, 2006,7 ( 9 ) : 735-740.
  • 10Hollenbeck BK,Taub DA, Miller DC, et al. National utilization trends of partial nephrectomy for renal cell carcinoma:a case of under utili zation? [J]. Urology,2006,67(2) :254-259.

二级参考文献32

  • 1李炎唐.肾细胞癌剜出术远期疗效[J].中华泌尿外科杂志,1993,14(6):449-450. 被引量：9
  • 2任国平,余心如,史时芳,汤宏峰,丁伟.青少年肾细胞癌临床及病理形态学观察（附14例分析）[J].临床泌尿外科杂志,1996,11(1):21-23. 被引量：1
  • 3Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma[J].J Urol,1998, 51:203-205.
  • 4Dechet C B, Sebo T, Peter J, et al. Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults[J]. J Urol, 1999,162:1282-1285.
  • 5Neumann H P H, Bender B U, Berger D P,et al. Prevalence, morphology and biology of renal cell carcinoma in yon Hippel-Lindau disease compared to sporadic renal cell carcinoma[J]. J Urol, 1998,160:1248.
  • 6Uzzo R G, Novick A C. Nephron sparing surgery for renal tumors., indications, techniques and outcomes[J]. J Urol,2001,166:6.
  • 7McLean G K, Meranze S G. Embolization techniques in the urinary tract [J]. Urol Clin N Amer,1985 ,12:743.
  • 8Shekarriz B, Upadhyay J, Shekarriz H, et al. Comparison of costs and complications of radical and partial nephrectomy for treatment of localized renal cell carcinoma[J]. Urology, 2002,59:211-215.
  • 9Bakal C W, Cynamon J, Lakritz P S, et al. Value of preoperative renal artery embolization in reducing blood transfusion requirements during nephrectomy for renal cell carcinoma[J]. J Vasc Intervent Rad, 1993,4:727.
  • 10Anup R P,Mihir D M, Andrew S P. Complications of laparoscopic partial nephrectomy in 200 cases[J]. J Urol,2005, 173(1):42-47.

共引文献38

同被引文献58

  • 1高平,李巍,鲍雷.大肠癌组织中增殖细胞核抗原(PCNA)和微血管密度(MVD)的表达及临床意义[J].中国医药指南,2008,6(16):545-546. 被引量：3
  • 2贾军,边富杰,赵宝东.转化生长因子β在骨缺损修复过程中对骨痂内ALP和钙的影响[J].实用诊断与治疗杂志,2007,21(3):176-177. 被引量：2
  • 3Harshman LC,Yu RJ,Allen GI,et al. Surgical outcomes and compli - cations associated with presurglcal tyrosine kinase inhibition for advanced renal cell carcinoma (RCC) [J]. Urol. Oncol, 2013,31: 379-385.18.
  • 4Guo J, Huang YR,Zhang X,et al.Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy:an open-label phase lb study[J]. BMC Cancer,2013,13:136.
  • 5National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer.2013.V1.May 12th,2012.
  • 6Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma:results from a large pooled analysis[J].Br J Cancer,2013,108:311-318.
  • 7Bergmann L,Goebell PJ,Kube U,et al.Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study[J]. Oncology,2013,36:95-100.
  • 8Gupta K, Miller JD, Li JZ, et al. Epidemiologic and so- cioeconomic burden of metastatic renal cell carcinoma (mRCC):a literature review [J].Cancer Treat Rev, 2008, 34(3):193-205.
  • 9Silverman SG, Israel GM, Herts BR, et al. Management of the incidental renal mass [ J ]. Radiology, 2008, 249 (1) :16-31.
  • 10Milonas D, Skulcius G, Baltrimavicius R, et al. Compar- ison of long-term results after nephron-sparing surgery and radical nephrectomy in treating 4- to 7-cm renal cell carci- noma [ J ]. Medicina ( Kaunas), 2013, 49 ( 5 ) : 223-228.

引证文献5

二级引证文献22

中华全科医学
2010年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部